Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP14 | Q460N5 | 2/20 | 0.44 |
| ▸ | TNKS | O95271 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 4/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | CCNK | O75909 | 2/20 | 0.39 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | ATAD2 | Q6PL18 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3443035 | 0.99 | PARP14 (0.43) | PARP14TNKSHTR2CPARP1CCNK | |
| SCHEMBL3442265 | 0.92 | TNKS (0.46) | PARP14TNKSHTR2CPARP1BRD4 | |
| Hydrochloric Acid SCHEMBL3442524 | 0.90 | HTR2C (0.47) | PARP14TNKSHTR2CPARP1BRD4 | |
| SCHEMBL6646094 | 0.78 | TNKS (0.50) | PARP14TNKSPARP1 | |
| Hydrochloric Acid SCHEMBL3442222 | 0.78 | KDM4E (0.44) | — | |
| SCHEMBL6645436 | 0.77 | PARP1 (0.44) | PARP14TNKSPARP1 | |
| SCHEMBL6644271 | 0.76 | PARP1 (0.43) | TNKSPARP1BRD4ATAD2 | |
| SCHEMBL6642750 | 0.76 | PARP1 (0.43) | PARP14TNKSPARP1 | |
| SCHEMBL6645162 | 0.76 | PARP1 (0.46) | PARP14TNKSPARP1 | |
| SCHEMBL6647500 | 0.75 | TNKS (0.46) | PARP14TNKSPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812178-B2 | Isoquinoline compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-10-12 | — | — | US | disclosed |
| US-20090076276-A1 | ISOQUINOLINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-19 | — | — | US | disclosed |
| US-7459465-B2 | Isoquinoline compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-12-02 | — | — | US | disclosed |
| US-20070161620-A1 | ISOQUINOLINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-12 | — | — | US | disclosed |
| US-7220759-B2 | Isoquinoline compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-05-22 | — | — | US | disclosed |
| EP-1557414-A1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2005-07-27 | — | — | EP | disclosed |
| US-20040248931-A1 | Isoquinoline compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248931-A1 | Isoquinoline compound and pharmaceutical use thereof | NQO1, PARP1, PARP11 | PARP14 6/4885TNKS 193/4885HTR2C 2493/4885 |
| US-20090076276-A1 | ISOQUINOLINE COMPOUND AND PHARMACEUTICAL USE THEREOF | NQO1, PARP1, NUDT1 | PARP14 7/4885TNKS 201/4885HTR2C 2471/4885 |
| US-20070161620-A1 | ISOQUINOLINE COMPOUND AND PHARMACEUTICAL USE THEREOF | NQO1, PARP1, NUDT1 | PARP14 7/4885TNKS 201/4885HTR2C 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.